Anti-TNFSF2/TNFa Antibody (hMAK195) is a humanized monoclonal antibody targeting tumor necrosis factor alpha (TNF-alpha/TNFSF2), serving as a biosimilar to Afelimomab. TNF-alpha is a critical pro-inflammatory cytokine primarily produced by macrophages and T cells, playing a central role in inflammatory responses, apoptosis, and immune regulation. hMAK195 specifically binds to both soluble and membrane-bound TNF-alpha, blocking their interaction with cell surface receptors (TNFR1 and TNFR2) and thereby inhibiting the activation of downstream NF-kappaB and MAPK signaling pathways. This antibody effectively neutralizes TNF-alpha-induced cytotoxicity and inflammatory cascades, making it a valuable tool for researching sepsis, rheumatoid arthritis, and other inflammatory diseases.
Target:
TNF
T9901A-1273
* VAT and and shipping costs not included. Errors and price changes excepted
